Bio Platforms

NANOPARTICLES – A Revolution in the Development of Drug Delivery Vehicles

Tim Leaver explains how his company has developed a proprietary technology for the rapid development of nanoparticles and seamless scale-up for clinical studies and commercial production, and how it is transforming the development and manufacturing of a range of nanoparticle formulations from a hit-and-miss affair to a standardized process, accelerating novel nanomedicines from the bench to the clinic.

EXCLUSIVE ONLINE CONTENT

9/5/2019

DURECT Earns $10-Million Milestone Payment From Gilead

DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….